Mechanisms of endotoxin neutralization by synthetic cationic compounds.
A basic challenge in the treatment of septic patients in critical care units is the release of bacterial pathogenicity factors such as lipopolysaccharide (LPS, endotoxin) from the cell envelope of Gram-negative bacteria due to killing by antibiotics. LPS aggregates may interact with serum and membrane proteins such as LBP (lipopolysaccharide-binding protein) and CD14 leading to the observed strong reaction of the immune system. Thus, an effective treatment of patients infected by Gram-negative bacteria must comprise beside bacterial killing the neutralization of endotoxins. Here, data are summarized for synthetic compounds indicating the stepwise development to very effective LPS-neutralizing agents. These data include synthetic peptides, based on the endotoxin-binding domains of natural binding proteins such as lactoferrin, Limulus anti-LPS factor, NK-lysin, and cathelicidins or based on LPS sequestering polyamines. Many of these compounds could be shown to act not only in vitro, but also in vivo (e.g. in animal models of sepsis), and might be useful in future clinical trials and in sepsis therapy.
Andrä
Jörg
J
Forschungszentrum Borstel, Biophysics Division, Leibniz-Zentrum für Medizin und Biowissenschaften, Borstel, Germany.
Gutsmann
Thomas
T
Garidel
Patrick
P
Brandenburg
Klaus
K
D002412:Cations / Q000737:chemistry*; D004731:Endotoxins / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D006801:Humans; D008070:Lipopolysaccharides / Q000037:antagonists & inhibitors / Q000378:metabolism; D018448:Models, Immunological; D009500:Neutralization Tests; D010455:Peptides / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology / Q000627:therapeutic use*
D002412:Cations; D004731:Endotoxins; D008070:Lipopolysaccharides; D010455:Peptides